论文部分内容阅读
目的探讨蛋白支持疗法对妊娠期肾病综合征的疗效及对妊娠结局的影响。方法选取2013年5月-2015年5月治疗的妊娠期肾病综合征患者76例,随机将其分为观察组和对照组各38例。对照组给予控制血压及对症处理,观察组在对照组治疗的基础上采用蛋白支持疗法治疗,对比两组患者治疗后的肾脏指标、妊娠结局及并发症发生情况。结果两组患者治疗后24 h尿蛋白、白蛋白、Ua、Cr、水肿消退平均时间、新生儿平均出生体重及早产儿发生率差异均有统计学意义(P<0.05),两组患者的腹腔积液及胸腔积液差异有统计学意义(P<0.05),而两组患者的贫血、产后出血差异无统计学意义(P>0.05)。结论蛋白支持疗法对妊娠期肾病综合征具有较好的疗效,可以有效地改善机体的低蛋白血症,改善妊娠结局,值得临床推广。
Objective To investigate the effect of protein support therapy on gestational nephrotic syndrome and its effect on pregnancy outcome. Methods Totally 76 patients with gestational nephrotic syndrome treated in May 2013-May 2015 were randomly divided into observation group (38 cases) and control group (38 cases). The control group was given blood pressure control and symptomatic treatment. The observation group was treated with protein support therapy on the basis of the control group. The renal indexes, pregnancy outcome and complications of the two groups were compared. Results The urinary albumin, albumin, Ua, Cr, the mean time to edema, the average birth weight and the incidence of premature infants in 24 hours after treatment in both groups were significantly different (P <0.05). The abdominal cavity area (P <0.05). There was no significant difference between the two groups in anemia and postpartum hemorrhage (P> 0.05). Conclusion The protein supportive therapy has a good curative effect on nephrotic syndrome in pregnancy, which can effectively improve the hypoproteinemia and improve the pregnancy outcome, which deserves clinical promotion.